O. Koch

发表

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma

C. Straka, W. Berdel, A. Heinecke, 2003, British journal of haematology.

Prognostic Value of Hemoglobin Concentrations in Patients with Advanced Head and Neck Cancer Treated with Combined Radio-Chemotherapy and Surgery

R. Hermann, W. Wagner, J. Hartlapp, 2000, Strahlentherapie und Onkologie.

Surgery in the tri-modality treatment of small cell lung cancer. Stage-dependent survival.

W. Wagner, F. Klinke, U. Vogt, 2006, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

A phase II single-institution study of neoadjuvant stage IIIA/B chemotherapy and radiochemotherapy in non-small cell lung cancer.

W. Wagner, F. Klinke, U. Bosse, 2003, The Annals of thoracic surgery.

8. Rodel C, Grabenbauer Gg, Kuhn R Et Al.. Combined-modality Treatment and Selective Organ Preservation in Invasive Bladder Cancer: Long-term Results. Comparing Long-term Toxicity and Efficacy of Combined Modality Treatment including Extended-or Involved-field Radiotherapy in Early-stage Hodgkin's L

H. Eich, R. Müller, V. Diehl, 2022 .

[Spontaneous regression of liver metastases in neuroendocrine tumors of the abdomen].

F. Christ, O. Koch, B. Siewert, 1991, Ultraschall in der Medizin.

Mixed response after allogeneic haemopoietic-cell transplantation for metastatic renal-cell carcinoma.

G. Baretton, G. Ehninger, M. Bornhäuser, 2004, The Lancet Oncology.

Prognostic factors of resected node-positive lung cancer: location, extent of nodal metastases, and multimodal treatment

C. Müller-Tidow, A. Marra, L. Hillejan, 2011, Thoracic surgical science.

Clinical management of breast cancer in males: a report of four cases.

C. Jackisch, A. Rody, H. Schneider, 2002, European journal of obstetrics, gynecology, and reproductive biology.

High-dose cytosine arabinoside and mitoxantrone: preliminary results of a pilot study with sequential application (S-HAM) indicating a high antileukemic activity in refractory acute leukemias.

W. Hiddemann, T. Büchner, J. van de Loo, 1988, Onkologie.

Combination of chemotherapy and interferon alfa-2b in the treatment of chronic myelogenous leukemia.

B. Wörmann, R. Nowak, M. Freund, 1993, Seminars in hematology.

Fatigue as an important aspect of quality of life in patients with acute myeloid leukemia.

W. Berdel, A. Heinecke, T. Büchner, 2002, Leukemia research.

Interferon-α2b in the Treatment of Chronic Myeloid Leukemia

W. Hiddemann, C. Fonatsch, B. Wörmann, 1992 .

Interferon-α2b in Chronic Myelogenous Leukemia: Experience with Two Treatment Regimen

W. Hiddemann, C. Fonatsch, M. Freund, 1990 .

Maintenance of dose intensity in adjuvant chemotherapy of breast cancer in patients treated outside a clinical trial: Results of a retrospective study

W. Eiermann, C. Jackisch, A. Rody, 2003 .

Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma.

H. Eich, R. Müller, P. Borchmann, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Synergistic growth inhibitory effects of interferon-alpha and lovastatin on bcr-abl positive leukemic cells.

Carsten Müller-Tidow, Hubert Serve, Wolfgang E Berdel, 2003, International journal of oncology.